Literature DB >> 15298658

Cigarette smoking among patients with schizophrenia and bipolar disorders.

Alp Uçok1, Aslihan Polat, Oya Bozkurt, Handan Meteris.   

Abstract

The purpose of the present study was to investigate the ratio of smokers and the relationship of cigarette smoking to clinical features in patients with schizophrenia and bipolar disorders. One hundred and forty-four patients with schizophrenia or bipolar disorder along with 114 healthy controls were evaluated. A total of 57.5% of the patients with schizophrenia, 55.1% of the bipolar patients and 47.3% of the control group were smokers. Daily cigarette consumption among the patients with schizophrenia was higher than that for the bipolar patients, and control group. Among the patients with schizophrenia who were in acute psychotic episode, Scale for the Assessment of Positive Symptoms scores of the smokers were significantly higher.

Entities:  

Mesh:

Year:  2004        PMID: 15298658     DOI: 10.1111/j.1440-1819.2004.01279.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  13 in total

1.  Nicotine intake and smoking topography in smokers with bipolar disorder.

Authors:  Jill M Williams; Kunal K Gandhi; Shou-En Lu; Marc L Steinberg; Neal L Benowitz
Journal:  Bipolar Disord       Date:  2012-09       Impact factor: 6.744

2.  Prevalence of Substance Use in Patients Diagnosed with Schizophrenia.

Authors:  Yasemin Tekin Uludağ; Gülcan Güleç
Journal:  Noro Psikiyatr Ars       Date:  2016-03-01       Impact factor: 1.339

3.  Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia.

Authors:  Deepak Cyril D'Souza; Irina Esterlis; Michelle Carbuto; Maegan Krasenics; John Seibyl; Frederic Bois; Brian Pittman; Mohini Ranganathan; Kelly Cosgrove; Julie Staley
Journal:  Am J Psychiatry       Date:  2012-03       Impact factor: 18.112

4.  A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia.

Authors:  Peggy Postma; Jeffrey A Gray; Tonmoy Sharma; Mark Geyer; Ravi Mehrotra; Mrigen Das; Elizabeth Zachariah; Melissa Hines; Steven C R Williams; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2006-02-02       Impact factor: 4.530

5.  Smoking in schizophrenia: diagnostic specificity, symptom correlates, and illness severity.

Authors:  Roman Kotov; Lin T Guey; Evelyn J Bromet; Joseph E Schwartz
Journal:  Schizophr Bull       Date:  2008-06-17       Impact factor: 9.306

6.  In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia.

Authors:  Irina Esterlis; Mohini Ranganathan; Frederic Bois; Brian Pittman; Marina R Picciotto; Lara Shearer; Alan Anticevic; Jon Carlson; Mark J Niciu; Kelly P Cosgrove; D Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2013-11-13       Impact factor: 13.382

7.  Smoking topography and outcome expectancies among individuals with schizotypy.

Authors:  Diana W Stewart; Christine Vinci; Claire E Adams; Alex S Cohen; Amy L Copeland
Journal:  Psychiatry Res       Date:  2012-12-20       Impact factor: 3.222

8.  Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.

Authors:  Deanna L Kelly; Robert P McMahon; Elaine Weiner; Douglas L Boggs; Dwight Dickinson; Robert R Conley; Robert W Buchanan
Journal:  Schizophr Res       Date:  2008-06-11       Impact factor: 4.939

9.  Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder.

Authors:  Richard C McEachin; Nancy L Saccone; Scott F Saccone; Yelena D Kleyman-Smith; Tiara Kar; Rajesh K Kare; Alex S Ade; Maureen A Sartor; James D Cavalcoli; Melvin G McInnis
Journal:  BMC Med Genet       Date:  2010-01-26       Impact factor: 2.103

10.  Role of the central cholinergic system in the therapeutics of schizophrenia.

Authors:  Alvin V Terry
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.